John has more than a decade experience advising over 40 biopharmaceutical, medical device and diagnostics companies on M&A and licensing strategies, portfolio management, valuation and strategic direction. While at KR, John has led KR’s partnership deal term benchmarking effort. He has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during partnership deal negotiations. John has also been combining his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement. Previously, John was a senior consultant with SDG, where he received his training in advanced management science and advised numerous Fortune 500 companies in life sciences and other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal & Manges LLP where he focused on M&A and corporate finance. John earned a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa, and a JD from Stanford Law School, where he was an associate editor of the Stanford Law Review.